These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 14655322)

  • 1. [Attractiveness of France for clinical trials: evaluation of laboratories and promoters].
    d'Enfert J; Lassale C; Prod'homme P
    Therapie; 2003; 58(3):283-9. PubMed ID: 14655322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A survey on the position of France in international clinical research as assessed by pharmaceutical laboratories].
    Courcier-Duplantier S; Bouhours P; Pinton P; Sibenaler C; Lassale C;
    Therapie; 2004; 59(6):629-38. PubMed ID: 15789827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The attractive position of France in international clinical research: 2006 survey assessed by Leem (French pharmaceutical companies)].
    Courcier S; Sibenaler C; Couderc M; Trinquet F; Plétan Y; Lassale C;
    Therapie; 2006; 61(5):407-18. PubMed ID: 17243270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Attractiveness of France for international clinical research: 8th survey conducted by Leem (French association for pharmaceutical companies)].
    Galaup A; Barthélémy P; Pouletty-Lefebvre B; Béhier JM; Zetlaoui J; Borel T
    Therapie; 2018 Oct; 73(5):367-376. PubMed ID: 29753391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Attractiveness of France for international clinical trials in 2012: 6(th) survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Barthélémy P; Plétan Y; Courcier S
    Therapie; 2013; 68(1):1-18. PubMed ID: 23484655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. France's competitiveness in global pharmaceutical research: The situation is improving.
    d'Andon A; Galaup A; Fabron C; Detournay B; Borel T
    Therapie; 2021; 76(6):549-557. PubMed ID: 34053732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [France, an attractive country for international clinical research: 2010 survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Behier JM; Pletan Y; Courcier S
    Therapie; 2011; 66(1):1-15. PubMed ID: 21466772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [France, an attractive country for international clinical research: 2008 survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Plétan Y; Courcier S;
    Therapie; 2008; 63(5):345-57. PubMed ID: 19154705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing clinical grant costs.
    Glass HE; Hollander K
    Contemp Clin Trials; 2009 May; 30(3):221-6. PubMed ID: 19470309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Lassale C; Sibenaler C; Béhier JM; Plétan Y; Courcier S
    Therapie; 2008; 63(5):345-57. PubMed ID: 27392656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Courcier S; Sibenaler C; Couderc M; Trinquet F; Plétan Y; Lassale C; le Groupe de Travail Attractivité de la France du Leem
    Therapie; 2006; 61(5):407-18. PubMed ID: 27392823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pharmaceutical industry in France: the turning point of 1915].
    Bonnemain B
    Rev Hist Pharm (Paris); 2015 Dec; 63(388):399-422. PubMed ID: 26827550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical research and drug development in Latin America: weighing the pros and cons, talking about the future.
    Rodrigues DG
    J Investig Med; 2007 Jul; 55(5):223-9. PubMed ID: 17850733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The economics of therapeutic investigations (author's transl)].
    Poisvert M
    Anesth Analg (Paris); 1980; 37(9-10):619-20, 623-6. PubMed ID: 7469079
    [No Abstract]   [Full Text] [Related]  

  • 18. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving clinical trials cost management in biotech companies.
    Cavan BN
    Biotechnology (N Y); 1995 Mar; 13(3):226-8. PubMed ID: 9678940
    [No Abstract]   [Full Text] [Related]  

  • 20. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.